• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Workday Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

    11/29/23 8:11:02 AM ET
    $ATNF
    $ATXI
    $AULT
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATNF alert in real time by email

    Shares of Workday, Inc. (NASDAQ:WDAY) surged in pre-market trading after the company reported upbeat earnings results for its third quarter.

    Workday posted earnings of $1.56 per share, beating market estimates of $1.41 per share. Revenue of $1.87 billion topped the analyst consensus estimate of $1.848 billion.

    Workday anticipated fourth-quarter subscription revenue to be $6.598 billion while adjusted operating margins were estimated to be 23.8%.

    Piper Sandler maintained Workday with an Overweight and raised the price target from $275 to $300.

    Workday shares rose 9% to $258.70 in pre-market trading

    Here are some other stocks moving in pre-market trading.

    Gainers

    • 180 Life Sciences Corp. (NASDAQ:ATNF) shares rose 55.2% to $0.5230 in pre-market trading after gaining around 8% on Tuesday. 180 Life Sciences recently announced a review of strategic alternatives.
    • RedHill Biopharma Ltd. (NASDAQ:RDHL) shares rose 47.3% to $3.36 in pre-market trading after jumping 128% on Tuesday. Redhill Biopharma recently announced the FDA has granted five years' market exclusivity for Talicia.
    • Avenue Therapeutics, Inc. (NASDAQ:ATXI) rose 39.4% to $0.2649 in pre-market trading. Avenue Therapeutics recently posted a profit for the third quarter.
    • Yoshiharu Global Co. (NASDAQ:YOSH) shares surged 26.1% to $6.04 in pre-market trading after gaining over 22% on Tuesday.
    • Ault Alliance, Inc. (NYSE:AULT) shares rose 24% to $0.1007 in pre-market trading. Ault Alliance Executive Chairman Milton C. Ault III acquired a total of 350,144 shares at an average price of $0.09.
    • Kelso Technologies Inc. (NYSE:KIQ) gained 23.4% to $0.2020 in pre-market trading. Kelso Technologies recently reported an increase in third-quarter sales.
    • Fluence Energy, Inc. (NASDAQ:FLNC) shares climbed 20% to $24.32 in pre-market trading after reporting fourth-quarter results. Fluence Energy also initiated FY24 revenue guidance of $2.7 billion to $3.3 billion.
    • Biomea Fusion, Inc. (NASDAQ:BMEA) shares gained 19.4% to $11.87 in pre-market trading.
    • GameStop Corp. (NYSE:GME) gained 15.3% to $15.55 in pre-market trading after gaining around 13% on Tuesday.

    Losers

    • Seelos Therapeutics, Inc. (NASDAQ:SEEL) dipped 39.9% to $1.43 in pre-market trading after the company reported pricing of $5.55 million public offering.
    • Leslie's, Inc. (NASDAQ:LESL) shares fell 15% to $4.95 in pre-market trading after the company reported mixed fourth-quarter financial results.
    • ESGL Holdings Limited (NASDAQ:ESGL) fell 12.3% to $1.14 in pre-market after jumping 45% on Tuesday. ESGL recently announced a multi-year contract renewal with Singapore Refining Company Private Limited.
    • SMX (Security Matters) Public Limited Company (NASDAQ:SMX) shares fell 12% to $1.03 in pre-market trading. SMX recently announced planned launch of world's first plastic cycle token.
    • Verve Therapeutics, Inc. (NASDAQ:VERV) shares fell 11.2% to $10.60 in pre-market trading after the company reported pricing of public offering of common stock and concurrent private placement.
    • HNR Acquisition Corp (NASDAQ:HNRA) fell 10.7% to $3.25 in pre-market trading. HNR Acquisition shares jumped 110% on Tuesday after the company gave a business update.
    • Smart for Life, Inc. (NASDAQ:SMFL) shares fell 10.3% to $1.38 in pre-market trading. Smart For Life recently announced a 1-for-3 reverse stock split.
    • Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) shares fell 9.6% to $3.75 in pre-market trading. Biodexa Pharmaceuticals shares fell over 18% on Tuesday after the company announced an offering of 1,397,849 Class A units at an assumed public offering price of $2.79 per Class A unit.
    • Impel Pharmaceuticals Inc. (NASDAQ:IMPL) fell 9.4% to $0.5410 in pre-market trading.
    • Okta, Inc. (NASDAQ:OKTA) fell 7.3% to $67.29 in pre-market trading. Okta disclosed that a data breach has affected all users of its customer support system.

     

    Now Read This: Dollar Tree, Salesforce And 3 Stocks To Watch Heading Into Wednesday

    Get the next $ATNF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATNF
    $ATXI
    $AULT
    $BDRX

    CompanyDatePrice TargetRatingAnalyst
    Okta Inc.
    $OKTA
    4/20/2026$90.00Equal Weight → Overweight
    Barclays
    Fluence Energy Inc.
    $FLNC
    4/17/2026$8.00Neutral → Sell
    UBS
    Okta Inc.
    $OKTA
    4/16/2026$85.00Mkt Perform → Outperform
    Raymond James
    Fluence Energy Inc.
    $FLNC
    3/20/2026Hold
    Needham
    Okta Inc.
    $OKTA
    3/19/2026$100.00Outperform
    Macquarie
    Fluence Energy Inc.
    $FLNC
    3/19/2026Sell → Neutral
    Guggenheim
    Okta Inc.
    $OKTA
    3/6/2026$97.00Market Perform → Outperform
    BMO Capital Markets
    Okta Inc.
    $OKTA
    3/3/2026$76.00Equal Weight
    Wells Fargo
    More analyst ratings

    $ATNF
    $ATXI
    $AULT
    $BDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Raday Gilead

    4 - RedHill Biopharma Ltd. (0001553846) (Issuer)

    4/22/26 6:09:14 PM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Schellhase David

    4 - Okta, Inc. (0001660134) (Issuer)

    4/20/26 5:08:55 PM ET
    $OKTA
    Computer Software: Prepackaged Software
    Technology

    SEC Form 4 filed by Robinson Mark Haymond

    4 - GameStop Corp. (0001326380) (Issuer)

    4/15/26 6:45:04 PM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    $ATNF
    $ATXI
    $AULT
    $BDRX
    SEC Filings

    View All

    SEC Form 8-K filed by Okta Inc.

    8-K - Okta, Inc. (0001660134) (Filer)

    4/22/26 4:21:09 PM ET
    $OKTA
    Computer Software: Prepackaged Software
    Technology

    SEC Form 6-K filed by Redhill Biopharma Ltd.

    6-K - RedHill Biopharma Ltd. (0001553846) (Filer)

    4/22/26 8:02:19 AM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Redhill Biopharma Ltd.

    6-K - RedHill Biopharma Ltd. (0001553846) (Filer)

    4/14/26 7:00:07 AM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $ATXI
    $AULT
    $BDRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TRUDHESA issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/13/21 2:21:35 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DIHYDROERGOTAMINE MESYLATE issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug DIHYDROERGOTAMINE MESYLATE (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/7/21 1:04:43 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $ATXI
    $AULT
    $BDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Okta upgraded by Barclays with a new price target

    Barclays upgraded Okta from Equal Weight to Overweight and set a new price target of $90.00

    4/20/26 8:21:07 AM ET
    $OKTA
    Computer Software: Prepackaged Software
    Technology

    Fluence downgraded by UBS with a new price target

    UBS downgraded Fluence from Neutral to Sell and set a new price target of $8.00

    4/17/26 8:08:09 AM ET
    $FLNC
    Industrial Machinery/Components
    Miscellaneous

    Okta upgraded by Raymond James with a new price target

    Raymond James upgraded Okta from Mkt Perform to Outperform and set a new price target of $85.00

    4/16/26 7:58:53 AM ET
    $OKTA
    Computer Software: Prepackaged Software
    Technology

    $ATNF
    $ATXI
    $AULT
    $BDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cheng Lawrence bought $114,368 worth of shares (5,000 units at $22.87) (SEC Form 4)

    4 - GameStop Corp. (0001326380) (Issuer)

    1/26/26 9:06:47 AM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    President, CEO and Chairman Cohen Ryan bought $21,359,200 worth of shares (1,000,000 units at $21.36), increasing direct ownership by 3% to 38,347,842 units (SEC Form 4)

    4 - GameStop Corp. (0001326380) (Issuer)

    1/22/26 4:02:03 PM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    Director Attal Alain bought $259,577 worth of shares (12,000 units at $21.63), increasing direct ownership by 2% to 596,464 units (SEC Form 4)

    4 - GameStop Corp. (0001326380) (Issuer)

    1/21/26 6:32:09 PM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    $ATNF
    $ATXI
    $AULT
    $BDRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OIO Group Completes De Tomaso Business Combination, Establishing New Control and Strategic Platform for Growth

    SINGAPORE, April 23, 2026 (GLOBE NEWSWIRE) -- OIO Group (NASDAQ:OIO) ("OIO" or the "Company") today announced the completion of its previously announced business combination with De Tomaso Automobili Holdings Limited ("De Tomaso"), resulting in a change of control of the Company. This milestone represents a transformational step for OIO as it advances its strategy to build a portfolio of distinctive, high-value operating businesses anchored in brand heritage, engineering excellence, and long-term value creation. As a result of the closing of the transaction, De Tomaso's founder, Norman Choi, becomes the controlling shareholder of OIO Group, positioning the Company under leadership with d

    4/23/26 4:38:00 PM ET
    $ESGL
    $OIO
    Environmental Services
    Utilities

    OIO Group Announces Reverse Stock Split Ahead of Nasdaq Listing and De Tomaso Business Combination

    SINGAPORE, April 22, 2026 (GLOBE NEWSWIRE) -- OIO Group (the "Company") today announced that its Board of Directors has approved a reverse stock split of the Company's issued and outstanding ordinary shares at a ratio of 1-for-3 (the "Reverse Stock Split"), which will become effective at 12:01 a.m. Eastern Time on April 24, 2026 (the "Effective Time"). The Reverse Stock Split will be effected in connection with, and immediately prior to, the concurrent closing of the Company's previously announced business combination with De Tomaso Automobili Holdings Limited ("De Tomaso") and the commencement of trading of the Company's ordinary shares on The Nasdaq Capital Market on a split-adjusted ba

    4/22/26 11:55:00 AM ET
    $ESGL
    $OIO
    Environmental Services
    Utilities

    RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026

    New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects of opaganib[1] as potential add-on therapy in models of neuroblastoma (NB) and triple-negative breast cancer (TNBC)The positive NB data from studies undertaken by Penn State University's Jeremy Hengst and Apogee Biotechnology, and funded by the Beat Childhood Cancer Foundation and Four Diamonds, indicate that opaganib may enhance the therapeutic efficacy of the oxaliplatin + doxorubicin (OXDOX) chemotherapy combination in high-risk NB by directly destabilizing n-Myc, a key oncogenic driver of neuroblastoma and other solid tumors, throu

    4/22/26 8:00:00 AM ET
    $CPIX
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $ATXI
    $AULT
    $BDRX
    Financials

    Live finance-specific insights

    View All

    Fluence Energy, Inc. Announces Second Quarter Earnings Release Date, Conference Call and Webcast

    ARLINGTON, Va., April 20, 2026 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (NASDAQ:FLNC) ("Fluence" or the "Company"), announced today that it will report earnings for the first quarter ended March 31st, 2026 on Wednesday, May 6th, 2026, after market close. The Company will conduct a teleconference starting at 8:30 a.m. EST on Thursday, May 7th, 2026, to discuss the results. To participate, analysts are required to register by clicking Fluence Energy Q2 2026 Earnings Call Registration Link. Once registered, analysts will be issued a unique PIN number and dial-in number. Analysts are encouraged to register at least 15 minutes before the scheduled start time. General audience participants, an

    4/20/26 4:30:00 PM ET
    $FLNC
    Industrial Machinery/Components
    Miscellaneous

    Workday Announces Date of Annual Stockholder Meeting on June 16, 2026

    PLEASANTON, Calif., March 26, 2026 /PRNewswire/ -- Workday, Inc. (NASDAQ:WDAY), the enterprise AI platform for managing people, money, and agents, today announced that its 2026 annual meeting of stockholders will be held virtually on Tuesday, June 16, 2026 at 9:00 a.m. Pacific Time / 12:00 p.m. Eastern Time. The record date for the meeting will be Friday, April 17, 2026 and only stockholders of record at the close of business on that date will be entitled to receive notice and vote upon matters considered at the meeting.Workday will make important information about the meeting a

    3/26/26 8:30:00 AM ET
    $WDAY
    EDP Services
    Technology

    GameStop Reports Fourth Quarter and Fiscal Year 2025 Results

    GameStop Corp. (NYSE:GME) ("GameStop" or the "Company") today released financial results for the fourth quarter and fiscal year ended January 31, 2026. The Company's consolidated financial statements, including GAAP and non-GAAP results, are below. The Company's Form 10-K and supplemental information can be found at https://investor.gamestop.com. FOURTH QUARTER OVERVIEW Net sales were $1.104 billion for the fourth quarter, compared to $1.283 billion in the prior year's fourth quarter. Selling, general and administrative ("SG&A") expenses were $241.5 million for the fourth quarter, compared to $282.5 million in the prior year's fourth quarter. Operating income was $135.2 million f

    3/24/26 4:02:00 PM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    $ATNF
    $ATXI
    $AULT
    $BDRX
    Leadership Updates

    Live Leadership Updates

    View All

    Preliminary Results for the Year Ended 31 December 2025

    March 27, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces its audited preliminary results for the year ended 31 December 2025. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFOTel: +44 (0)29 2048 0180www.biodexapharma.com About Biodexa The Company's lead development programs include eRapa, under development for Familial Adenoma

    3/27/26 5:00:00 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Workday Announces CEO Transition as Co-Founder Aneel Bhusri Returns to Lead the Company's Next Chapter

    Carl Eschenbach Steps Down After Leading Company Through a Period of Global Expansion and Operational Scale Company Reaffirms Fiscal 2026 Fourth Quarter and Full-Year Outlook PLEASANTON, Calif., Feb. 9, 2026 /PRNewswire/ -- Workday, Inc. (NASDAQ:WDAY), the enterprise AI platform for managing people, money, and agents, today announced that co-founder and current executive chair Aneel Bhusri is returning as chief executive officer as the company enters its next chapter, focused on leading in the rapidly evolving AI era. Carl Eschenbach is stepping down as CEO and as a member of the board after leading Workday through a period defined by global growth, an expanded industry focus, and strengthen

    2/9/26 8:30:00 AM ET
    $WDAY
    EDP Services
    Technology

    Workiva Announces Two New Appointments to Board of Directors

    Company Appoints Former Cisco and Autodesk CFO Scott Herren and Former Workday Co-President, CFO, and EVP Mark Peek Workiva Inc. (NYSE:WK), a leading, AI-powered platform for trust, transparency, and accountability, today announced the appointment of two new independent directors to its Board of Directors. Scott Herren is the former EVP and Chief Financial Officer of Cisco and current Board member and Audit Committee Chair at Rubrik (NYSE:RBRK). Mark Peek is a former EVP, CFO, and Co-President of Workday (NASDAQ:WDAY) and currently sits on the Board of Directors for SentinelOne (NYSE:S) and Trimble (NASDAQ:TRMB). "We are pleased to welcome two highly experienced SaaS leaders to our Boar

    1/28/26 4:05:00 PM ET
    $RBRK
    $S
    $TRMB
    Computer Software: Prepackaged Software
    Technology
    Industrial Machinery/Components
    Industrials

    $ATNF
    $ATXI
    $AULT
    $BDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Seelos Therapeutics Inc.

    SC 13G/A - SEELOS THERAPEUTICS, INC. (0001017491) (Subject)

    12/4/24 1:29:12 PM ET
    $SEEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/20/24 11:56:39 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Verve Therapeutics Inc.

    SC 13G - Verve Therapeutics, Inc. (0001840574) (Subject)

    11/18/24 5:23:52 PM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care